Experts discuss the use of Simple Plex immunoassays on Ella to monitor the cellular immune response to SARS-CoV-2 in real time.
To watch this webinar, please contact Bio-Techne at: email@example.com.
Ella enables the rapid and high quality cytokine and pro inflammatory biomarker monitoring in support of disease severity and progression research in a multi-analyte, automated and standardized format.
Carmen Cámara Hijón, PhD – Usefulness of Cytokine Measurement to Support Decision-Making in Patients with COVID-19
The correct characterization of the immune response induced by SARS-Cov-2 includes the pattern of cytokines in peripheral blood. Dr. Carmen Camara discusses how assaying cytokine profiles allows us not only to establish a cause-effect relationship in unusual conditions (e.g. chiblain lesions and COVID-19) but even to make therapeutic decisions in some of them (e.g. pediatric multisystemic inflammatory syndrome).
She also describes a fast and cost-efficient method of measuring the cellular response induced by vaccines by measuring IFN-γ and IL-2 after whole-blood overnight stimulation with SARS-CoV-2 peptides, to identify the correlate of immunity in patients at risk, such as those with primary immunodeficiencies.
Martina Fabris, MD – Cytokines and COVID-19: The Value in Risk Stratification Within the First 72 Hours of Hospitalization
It is increasingly clear that the immune response to COVID-19, and not the pathogen itself, is responsible for the exaggerated release of inflammatory molecules during infection. Several cytokines play a key role in SARS-CoV-2 pathogenesis and can help to identify patients with worse prognosis or in a different phase of the pathological process. However, these cytokines can be difficult to assay, and we do not yet understand their relationship with classic inflammatory markers like CRP.
Dr. Martina Fabris discusses which cytokines, alongside standard markers of systemic inflammation, are most valuable in identifying patients at a high risk of an unfavorable outcome, and on the other hand, low-risk patients who can reasonably be discharged from the hospital. She also describes the challenge of using these new biomarkers effectively in daily clinical practice to support complicated diagnoses, to evaluate risk more effectively, and to ensure increasingly targeted therapies.
DISCLAIMER: The Ella™ automated immunoassay platform is currently offered for research use only; not for use in diagnostic procedures.
To retrieve a PDF copy of the presentation, click on the link below the slide player. From this page, click on the “Download” link to retrieve the file.
Unidad de Inmunología
Hospital Universitario La Paz
Diagnostics of Autoimmune Diseases
University of Udine (UNIUD)